Covered recipient · General Payments record
JULIUS O AJAYI
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$4,261.17
- Reported across 191 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $419.15 | 13 |
| Education | $90.00 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $121.84 | 1 |
| Astellas Pharma US Inc | $108.60 | 2 |
| Inspire Medical Systems, Inc. | $57.52 | 1 |
| Novo Nordisk AS | $55.13 | 3 |
| Lilly USA, LLC | $39.07 | 2 |
| Exact Sciences Corporation | $30.85 | 1 |
| Acerta Pharma LLC | $29.83 | 1 |
| Teleflex LLC | $25.72 | 1 |
| PFIZER INC. | $22.25 | 1 |
| GlaxoSmithKline, LLC. | $18.34 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (14)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Astellas Pharma US Inc | $18.60 | 01/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139278868 | CMS |
| Astellas Pharma US Inc | $90.00 | 02/19/2024 | Education | Undisputed | 01/23/2026 | 1139343626 | CMS |
| AstraZeneca Pharmaceuticals LP | $29.83 | 12/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104275333 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $121.84 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086194952 | CMS |
| Exact Sciences Corporation | $30.85 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114571935 | CMS |
| GlaxoSmithKline, LLC. | $18.34 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116715115 | CMS |
| Inspire Medical Systems, Inc. | $57.52 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148039114 | CMS |
| Lilly USA, LLC | $18.26 | 01/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135092549 | CMS |
| Lilly USA, LLC | $20.81 | 08/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135102167 | CMS |
| Novo Nordisk Inc | $16.95 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097687560 | CMS |
| Novo Nordisk Inc | $14.43 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096678555 | CMS |
| Novo Nordisk Inc | $23.75 | 12/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096573582 | CMS |
| PFIZER INC. | $22.25 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131998649 | CMS |
| Teleflex LLC | $25.72 | 07/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1142083602 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.